Hot Prescriber Trend: GLP-1 Utilizers in Obesity Treatment Shifting to Phentermine Scripta Jun 21, 2024 2 min read Updated: Jun 24, 2024 Thanks to clinical trials that demonstrated a 12% weight-loss(1) and much buzzed about appetite-suppressing effects, the GLP-1 weight loss medications Wegovy and Zepbound, has been all over the news, and so has its high price tag
Acta 1830 , 33503353 (2013)
However, there isnt enough data to determine whether using a KPV peptide is safe or effective, because most of the research has involved cells and animals, not actual people
Dipeptidyl peptidase IV (DPP IV) inhibitors: A newly emerging drug class for the treatment of type 2 diabetes
In 2025, Evernorth excluded Wegovy from approximately 22% of employer plans in favor of compounded semaglutide or no coverage at all (Conklin et al., Health Affairs 2025)
This peptide has been the subject of extensive preclinical investigation across multiple biological systems